Table 2.
Study characteristics.
| Author | Tracer | Injected Dose (MBq) | Uptake Time (min) | Machine | PET Timing | PET Response Criteria |
|---|---|---|---|---|---|---|
| Acar [15] | 68Ga-PSMA-I&T | 115 * | 60 | PET/CT | after last cycle | SUVpeak SUVmax PSMA-TV TL-PSMA |
| Ahmadzadehfar [16] | 68Ga-PSMA-11 | 2/kg | 77 † | PET/CT | after last cycle | PSMA expression (not explicit) |
| Grubmüller [17] | 68Ga-PSMA-11 | 2/kg | 60 | PET/CT or PET/MRI | after 3 cycle | PSMA-TV Summed SUVmean |
| Grubmüller [18] | 68Ga-PSMA-11 | 2/kg | 60 | PET/CT or MRI |
223Ra or systemic Tx.: after 6 cycle abiraterone or enzalutamide: at 3 mo. |
Summed SUVmax Summed SUVmean Summed SUVpeak PSMA-TV |
| Gupta [19] | 68Ga-PSMA-11 | 2/kg | 60 | PET/CT | after radionuclide therapy | SUVmax |
| Hartrampf [20] | 68Ga-PSMA-I&T | 119–125 * | 71–82 † | PET/CT | after completion or termination of chemotherapy | SUVmax PSMA-TV TL-PSMA |
| Heinzel [21] | 68Ga-PSMA-11 | 2/kg | 60 | PET/CT | after 3 or 4 cycle | SUVpeak |
| Michalski [22] | 68Ga-PSMA-11 | 206 * | 60 | PET/CT | after 2 cycle | SUVmax SUVmean Summed SUVmean PSMA-TV TL-PSMA |
| Ozulker [23] | 68Ga-PSMA-I&T | 2/kg | 60 | PET/CT | after ≥3 cycles | Summed SUVmax ‡ |
| Seitz [24] | 68Ga-PSMA-11 | 154 * | 57 * | PET/CT | after 3 cycle | Summed SUVpeak |
* mean; † Applicable, as individual patient data were available; ‡ An increase in 25% in accordance with EORTC criteria was defined as non-response. All the other studies set +30% following PERCIST 1.0; PSMA-TV = PSMA tumor volume; RECIST = The Response Evaluation Criteria in Solid Tumors; SUV = standardized uptake value; TL-PSMA = total lesion PSMA.